The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | FRESCO-2: subgroup analysis of fruquintinib in mCRC with liver metastases
Rocio Garcia-Carbonero, MD, PhD, University Hospital 12 De Octubre, Madrid, Spain, discusses a subgroup analysis of the FRESCO-2 trial (NCT04322539) of fruquintinib, a VEGFR inhibitor, in patients with metastatic colorectal cancer (mCRC), focusing on liver metastases. Fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) compared to placebo. Disease control rates were higher with fruquintinib, and adverse events, including hepatic function abnormalities, were comparable between groups as well. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
